Development of the novel LDL-receptor targeted liposome formulation for cancer treatment
1 In the proposed work, we planned to develop a novel liposomal paclitaxel formulation in PEGylated liposome conjugated with PCSK9 (PCSK9-PEGLip; PCSK9 conjugated Liposomes). Here we expected to combine the LDL-targeting properties of PCSK9 with the drug delivery properties of sterically stabilized...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Report |
Language: | unknown |
Published: |
2023
|
Subjects: | |
Online Access: | https://hdl.handle.net/10533/49139 |